MA49368A - Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires - Google Patents

Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Info

Publication number
MA49368A
MA49368A MA049368A MA49368A MA49368A MA 49368 A MA49368 A MA 49368A MA 049368 A MA049368 A MA 049368A MA 49368 A MA49368 A MA 49368A MA 49368 A MA49368 A MA 49368A
Authority
MA
Morocco
Prior art keywords
imidazopyrimidines
diazabicyclic
substitute
respiratory tract
tract diseases
Prior art date
Application number
MA049368A
Other languages
English (en)
Other versions
MA49368B1 (fr
Inventor
Udo Albus
Moritz Beck-Broichsitter
Karl Collins
Martina Delbeck
Doris Gehring
Michael Hahn
Niels Lindner
Klemens Lustig
Thomas Müller
Janine Nicolai
Björn Rosenstein
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MA49368A publication Critical patent/MA49368A/fr
Publication of MA49368B1 publication Critical patent/MA49368B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA49368A 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires MA49368B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17176046 2017-06-14
EP17193252 2017-09-26
PCT/EP2018/064977 WO2018228907A1 (fr) 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
EP18728646.3A EP3638675B1 (fr) 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Publications (2)

Publication Number Publication Date
MA49368A true MA49368A (fr) 2021-04-14
MA49368B1 MA49368B1 (fr) 2024-06-28

Family

ID=62492660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49368A MA49368B1 (fr) 2017-06-14 2018-06-07 Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires

Country Status (36)

Country Link
US (3) US11098063B2 (fr)
EP (1) EP3638675B1 (fr)
JP (2) JP6896113B2 (fr)
KR (1) KR102364134B1 (fr)
CN (4) CN115583959B (fr)
AR (1) AR112099A1 (fr)
AU (1) AU2018283331B2 (fr)
BR (1) BR112019026450A2 (fr)
CA (1) CA3066942A1 (fr)
CL (1) CL2019003650A1 (fr)
CO (1) CO2019014047A2 (fr)
CR (1) CR20190563A (fr)
CU (1) CU24603B1 (fr)
DO (1) DOP2019000308A (fr)
EA (1) EA202090043A1 (fr)
EC (1) ECSP19088492A (fr)
ES (1) ES2985167T3 (fr)
GE (2) GEP20227366B (fr)
HR (1) HRP20240678T1 (fr)
HU (1) HUE066512T2 (fr)
IL (1) IL271117B (fr)
JO (1) JOP20190284A1 (fr)
MA (1) MA49368B1 (fr)
MX (2) MX2019014983A (fr)
MY (1) MY204293A (fr)
NI (1) NI201900126A (fr)
NZ (1) NZ758821A (fr)
PE (1) PE20200016A1 (fr)
PH (1) PH12019502828A1 (fr)
PL (1) PL3638675T3 (fr)
RS (1) RS65543B1 (fr)
SG (1) SG11201911508XA (fr)
TW (1) TWI801388B (fr)
UA (1) UA125186C2 (fr)
UY (1) UY37773A (fr)
WO (1) WO2018228907A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20180056A7 (es) 2015-12-10 2018-10-04 Bayer Pharma AG Derivados de 2-fenil-3-(piperazinometil)imidazo(1,2-a)piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios
JOP20190284A1 (ar) * 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2018227427A1 (fr) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Dérivés de diazépane pontés substitués et leur utilisation
US20220218695A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
US20220218700A1 (en) * 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
CN120025328A (zh) 2019-11-06 2025-05-23 拜耳公司 肾上腺素能受体adrac2拮抗剂
JP2023532658A (ja) * 2020-07-06 2023-07-31 バイエル・アクチエンゲゼルシヤフト 睡眠時無呼吸の治療のためのアルファ２－アドレナリン受容体サブタイプｃ（アルファ－２ｃ）拮抗薬とｔａｓｋ１／３チャネル遮断薬の組合せ
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
US20250057845A1 (en) 2021-12-22 2025-02-20 Bayer Aktiengesellschaft Combination of a task1/3 channel blocker with a p2x3 receptor antagonist for the treatment of sleep apnea
JP2024545696A (ja) 2021-12-22 2024-12-10 バイエル・アクチエンゲゼルシヤフト 睡眠時無呼吸の治療のためのｔａｓｋ１／３チャネル遮断薬とムスカリン受容体アンタゴニストとの組合せ
IL313648A (en) 2021-12-22 2024-08-01 Bayer Ag Combination of a TASK1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
AU2023205312A1 (en) 2022-01-07 2024-07-25 Ocular Therapeutix, Inc. 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea
KR20240132346A (ko) 2022-01-07 2024-09-03 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 α2-아드레날린수용체 서브타입 C 길항제
KR20260083348A (ko) 2023-09-28 2026-06-05 바이엘 악티엔게젤샤프트 치환된 헤테로시클릭 카르복스아미드 및 그의 용도
CN117959293B (zh) * 2024-01-18 2025-05-13 香港大学深圳医院 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6552037B2 (en) 2000-06-30 2003-04-22 Neurogen Corporation 2-Substituted imidazo[1,2-A]pyridine derivatives
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
CN101636154B (zh) 2006-04-27 2011-12-14 塞诺菲-安万特德国有限公司 Task-1和task-3离子通道抑制剂
EP2049110B1 (fr) * 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Diazépans pontés antagonistes du récepteur de l'oréxine
EP1974729A1 (fr) 2007-03-28 2008-10-01 Santhera Pharmaceuticals (Schweiz) AG Dérivés d'imidazopyridine substitués en tant qu'antagonistes du récepteur de la mélanocortine- 4
AU2009249186B2 (en) 2008-05-19 2014-05-22 Sunovion Pharmaceuticals Inc. Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
RU2576662C2 (ru) 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2590979A1 (fr) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Pyrimidines et triazines annelées et leur utilisation pour traiter ou prévenir des affections du système cardio-vasculaire
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
KR20140048079A (ko) 2011-02-01 2014-04-23 교와 핫꼬 기린 가부시키가이샤 축환 복소환 유도체
JP2014509616A (ja) 2011-03-31 2014-04-21 エーエムベーエルエーエム テクノロジー トランスファー ゲーエムベーハー 治療用イミダゾ［１，２−ａ］ピリジン化合物
WO2012143796A2 (fr) 2011-04-21 2012-10-26 Institut Pasteur Korea Composés anti-inflammatoires
MX2014002968A (es) 2011-09-12 2014-07-09 Sanofi Sa 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden.
ES2559450T3 (es) 2011-09-16 2016-02-12 Sanofi 4,5,6,7-Tetrahidro-1H-pirazolo[4,3-c]piridinas sustituidas, su uso como medicamento, y preparaciones farmacéuticas que las comprenden
WO2013037914A1 (fr) 2011-09-16 2013-03-21 Sanofi 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées, leur utilisation comme médicament, et préparations pharmaceutiques les contenant
DK2809669T3 (da) 2012-02-03 2017-05-01 Sanofi Sa Kondenserede pyrroldicarboxamider og deres anvendelse som farmaceutika
WO2014187922A1 (fr) * 2013-05-24 2014-11-27 Iomet Pharma Ltd. Inhibiteurs du transporteur slc2a
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
WO2016085784A1 (fr) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Antagonistes de récepteur d'orexine de type méthyl-diazépane
JP2018012645A (ja) * 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
TWI585785B (zh) 2014-11-26 2017-06-01 Murata Manufacturing Co Electronic parts manufacturing methods, electronic components and electronic devices
US9994570B2 (en) * 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
JP2018016544A (ja) 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ［２．２．２］オクタン誘導体
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
CU20180056A7 (es) 2015-12-10 2018-10-04 Bayer Pharma AG Derivados de 2-fenil-3-(piperazinometil)imidazo(1,2-a)piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios
WO2017097671A1 (fr) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Dérivés de perhydropyrrolo[3,4-c]pyrrole substitués et leur utilisation
JOP20190005A1 (ar) 2016-07-20 2019-01-20 Bayer Ag مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
WO2018227427A1 (fr) 2017-06-14 2018-12-20 Bayer Aktiengesellschaft Dérivés de diazépane pontés substitués et leur utilisation
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
PE20211285A1 (es) 2018-11-27 2021-07-19 Bayer Ag Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios
US20220218695A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea
US20220218700A1 (en) 2019-05-09 2022-07-14 Bayer Aktiengesellschaft Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea

Also Published As

Publication number Publication date
TW201919638A (zh) 2019-06-01
SG11201911508XA (en) 2020-01-30
CN115583959B (zh) 2024-04-26
CA3066942A1 (fr) 2018-12-20
NI201900126A (es) 2020-04-02
IL271117B (en) 2022-03-01
CU20190101A7 (es) 2020-10-20
MX2019014983A (es) 2020-02-24
PE20200016A1 (es) 2020-01-06
NZ758821A (en) 2025-05-02
HRP20240678T1 (hr) 2024-08-16
HUE066512T2 (hu) 2024-08-28
US12180227B2 (en) 2024-12-31
JP2020523388A (ja) 2020-08-06
JOP20190284A1 (ar) 2019-12-11
CN110719911A (zh) 2020-01-21
CL2019003650A1 (es) 2020-07-10
AU2018283331A1 (en) 2019-12-19
US11098063B2 (en) 2021-08-24
EA202090043A1 (ru) 2020-04-02
GEP20227366B (en) 2022-03-25
CU24603B1 (es) 2022-06-06
CO2019014047A2 (es) 2020-01-17
CN115554299A (zh) 2023-01-03
ES2985167T3 (es) 2024-11-04
JP6896113B2 (ja) 2021-06-30
KR102364134B1 (ko) 2022-02-18
GEAP202115256A (en) 2021-10-11
EP3638675C0 (fr) 2024-04-17
ECSP19088492A (es) 2019-12-27
CR20190563A (es) 2020-04-22
CN115554300A (zh) 2023-01-03
JP2021127346A (ja) 2021-09-02
US20220017540A1 (en) 2022-01-20
KR20200014915A (ko) 2020-02-11
CN115554300B (zh) 2024-10-29
AU2018283331B2 (en) 2022-08-04
MY204293A (en) 2024-08-21
CN115583959A (zh) 2023-01-10
UA125186C2 (uk) 2022-01-26
CN110719911B (zh) 2022-10-21
US20200109155A1 (en) 2020-04-09
DOP2019000308A (es) 2020-01-31
MX2022012716A (es) 2022-11-07
PH12019502828A1 (en) 2020-10-26
RS65543B1 (sr) 2024-06-28
IL271117A (en) 2020-01-30
AR112099A1 (es) 2019-09-18
PL3638675T3 (pl) 2024-07-01
UY37773A (es) 2019-01-02
EP3638675A1 (fr) 2020-04-22
US20250154175A1 (en) 2025-05-15
BR112019026450A2 (pt) 2020-07-14
EP3638675B1 (fr) 2024-04-17
WO2018228907A1 (fr) 2018-12-20
MA49368B1 (fr) 2024-06-28
TWI801388B (zh) 2023-05-11

Similar Documents

Publication Publication Date Title
FR22C1011I1 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3337465A4 (fr) Compositions et méthodes d'utilisation en association destinées au traitement et au diagnostic de maladies auto-immunes
EP3709882A4 (fr) Attelles diagnostiques et thérapeutiques
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
EP4268910C0 (fr) Système de gestion pour jeux de table et monnaie de substitution pour jeu
EP3273955A4 (fr) Traitement de maladies respiratoires
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
CY1126258T1 (el) Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων
MA44126A (fr) Méthodes de traitement de maladies et troubles pulmonaires
HUE037663T2 (hu) Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
EP2969010A4 (fr) Utilisation de levocetirizine et de montelukast dans le traitement des maladies auto-immunes
IL283469A (en) Inhalable preparations for use in the treatment of lung diseases
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
EP3729452C0 (fr) Système et procédé d'entraînement d'inhalateur
EP3634370A4 (fr) Traitement des troubles cutanés
IL257932A (en) Adapted cytotoxins and their therapeutic uses
PL3157522T3 (pl) Antagonisty muskarynowi i ich kombinacje do leczenia choroby dróg oddechowych u koni
EP3395341A4 (fr) Composition pour le traitement de maladies neuromotrices et son utilisation
EP3423461A4 (fr) Composés de sélénogalactoside pour la prévention et le traitement de maladies associées à la galectine et leur utilisation
EP2945953A4 (fr) Composés tétracycliques à substitution thiophène et leurs méhodes d'utilisation pour le traitement de maladies virales
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee